Anebulo Net Debt from 2010 to 2026
| ANEB Stock | USD 0.48 0.01 2.13% |
Net Debt | First Reported 2020-06-30 | Previous Quarter -10.4 M | Current Value -9 M | Quarterly Volatility 6.7 M |
Check Anebulo Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Anebulo Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Income of 311.4 K, Depreciation And Amortization of 220.8 K or Interest Expense of 461.3 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 4.56. Anebulo financial statements analysis is a perfect complement when working with Anebulo Pharmaceuticals Valuation or Volatility modules.
Anebulo | Net Debt | Build AI portfolio with Anebulo Stock |
Analyzing Anebulo Pharmaceuticals's Net Debt over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Net Debt has evolved provides context for assessing Anebulo Pharmaceuticals's current valuation and future prospects.
Latest Anebulo Pharmaceuticals' Net Debt Growth Pattern
Below is the plot of the Net Debt of Anebulo Pharmaceuticals over the last few years. It is the total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds. Anebulo Pharmaceuticals' Net Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Anebulo Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Debt | 10 Years Trend |
|
Net Debt |
| Timeline |
Anebulo Net Debt Regression Statistics
| Arithmetic Mean | (6,832,539) | |
| Coefficient Of Variation | (85.37) | |
| Mean Deviation | 5,156,093 | |
| Median | (2,823,694) | |
| Standard Deviation | 5,833,260 | |
| Sample Variance | 34T | |
| Range | 17.2M | |
| R-Value | (0.68) | |
| Mean Square Error | 19.5T | |
| R-Squared | 0.46 | |
| Significance | 0 | |
| Slope | (786,628) | |
| Total Sum of Squares | 544.4T |
Anebulo Net Debt History
Other Fundumenentals of Anebulo Pharmaceuticals
Anebulo Pharmaceuticals Net Debt component correlations
Click cells to compare fundamentals
About Anebulo Pharmaceuticals Financial Statements
Anebulo Pharmaceuticals stakeholders use historical fundamental indicators, such as Anebulo Pharmaceuticals' Net Debt, to determine how well the company is positioned to perform in the future. Although Anebulo Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Anebulo Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Anebulo Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Anebulo Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Debt | -13.4 M | -14 M | |
| Net Debt To EBITDA | 1.65 | 1.57 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Anebulo Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Anebulo Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anebulo Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anebulo Pharmaceuticals Stock:Check out the analysis of Anebulo Pharmaceuticals Correlation against competitors. For information on how to trade Anebulo Stock refer to our How to Trade Anebulo Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anebulo Pharmaceuticals. If investors know Anebulo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Anebulo Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Anebulo Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Anebulo Pharmaceuticals' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Anebulo Pharmaceuticals' market price to deviate significantly from intrinsic value.
Understanding that Anebulo Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Anebulo Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Conversely, Anebulo Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.